| 主权项 |
1. A pharmaceutical composition comprising:
A. A Compound of Formula I or a pharmaceutically acceptable salt thereof, wherein: Each of WRW2 and WRW4 is independently selected from CN, CF3, halo, C2-6 straight or branched alkyl, C3-12 membered cycloaliphatic, phenyl, a 5-10 membered heteroaryl or 3-7 membered heterocyclic, wherein said heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW2 and WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, CN, —COOR′, —COR′, —O(CH2)2N(R′)2, —O(CH2)N(R′)2, —CON(R′)2, —(CH2)2OR′, —(CH2)OR′, —CH2CN, optionally substituted phenyl or phenoxy, —N(R′)2, —NR′C(O)OR′, —NR′C(O)R′, —(CH2)2N(R′)2, or —(CH2)N(R′)2; WRW5 is selected from hydrogen, —OCF3, —CF3, —OH, —OCH3, —NH2, —CN, —CHF2, —NHR′, —N(R′)2, —NHC(O)R′, —NHC(O)OR′, —NHSO2R′, —CH2OH, —CH2N(R′)2, —C(O)OR′, —SO2NHR′, —SO2N(R′)2, or —CH2NHC(O)OR′; and Each R′ is independently selected from an optionally substituted group selected from a C1-8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R′ are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; provided that: iii) WRW2 and WRW4 are not both —Cl; WRW2, WRW4 and WRW5 are not —OCH2CH2Ph, —OCH2CH2(2-trifluoromethyl-phenyl), —OCH2CH2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl), or substituted 1H-pyrazol-3-yl; and B. A Compound of Formula II or pharmaceutically acceptable salts thereof, wherein:
ring A is selected from: R1 is —CF3, —CN, or —C≡CCH2N(CH3)2;R2 is hydrogen, —CH3, —CF3, —OH, or —CH2OH;R3 is hydrogen, —CH3, —OCH3, or —CN; provided that both R2 and R3 are not simultaneously hydrogen;optionally in combination with one or both of:
C. A Compound of Formula III or pharmaceutically acceptable salts thereof, wherein: T is —CH2—, —CH2CH2—, —CF2—, —C(CH3)2—, or —C(O)—; R1′ is H, C1-6 aliphatic, halo, CF3, CHF2, O(C1-6 aliphatic); and RD1 or RD2 is ZDR9 wherein:ZD is a bond, CONH, SO2NH, SO2N(C1-6 alkyl), CH2NHSO2, CH2N(CH3)SO2, CH2NHCO, COO, SO2, or CO; andR9 is H, C1-6 aliphatic, or aryl; and/or D. A Compound of Formula IV or pharmaceutically acceptable salts thereof, wherein: R is H, OH, OCH3 or two R taken together form —OCH2O— or —OCF2O—; R4 is H or alkyl; R5 is H or F; R6 is H or CN; R7 is H, —CH2CH(OH)CH2OH, —CH2CH2N+(CH3)3, or —CH2CH2OH; R8 is H, OH, —CH2CH(OH)CH2OH, —CH2OH, or R7 and R8 taken together form a five membered ring. |
